SLS 424B5: Secondary offering
Filed with the SEC on · accession 0001104659-26-129063
SLS filed a 424B5 (prospectus (offering)) with the SEC on Nov 17, 2026. SELLAS Life Sciences Group, Inc. launched a $150 million public offering of common stock, with an additional 30-day underwriter option for up to $22.5 million in shares. The stock moved +156.4% by the first close after the filing.
Summary of the filing
SELLAS Life Sciences Group, Inc. launched a $150 million public offering of common stock, with an additional 30-day underwriter option for up to $22.5 million in shares. The offering is being managed by J.P. Morgan and TD Cowen.
Key details
How SLS stock reacted
Close before
$7.47
Nov 16, 2026
First close after
+156.36%
$19.15
5 trading days
—
Since filing
+98.93%
$14.86
✦ Ask GOAX AI about this filing — what it means for SLS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SLS?
Click hereFrequently asked questions
What did SLS file with the SEC on Nov 17, 2026?
SLS filed a 424B5 (Secondary offering). SELLAS Life Sciences Group, Inc. launched a $150 million public offering of common stock, with an additional 30-day underwriter option for up to $22.5 million in shares. The offering is being managed by J.P. Morgan and TD Cowen.
What does a secondary offering mean for SLS stock?
New shares dilute existing holders and are often sold at a discount to the market price.
How do I read a 424B5?
The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B5 (prospectus (offering)): The final terms of an offering of shares or bonds.
How did SLS stock react to this filing?
SLS closed at $7.47 before the filing and $19.15 on Nov 17, 2026 (+156.36%).
Other SLS SEC filings
- 8-K · Fda approvalNov 17, 2026
- 10-Q · SEC filingNov 12, 2026
- 8-K · SEC filingNov 12, 2026
- SCHEDULE 13G · SEC filingNov 10, 2026
- SCHEDULE 13G/A · SEC filingOct 27, 2026
- 8-K · SEC filingAug 11, 2026
- 10-Q · SEC filingAug 11, 2026
- 8-K · SEC filingJul 27, 2026
- 8-K · SEC filingJun 25, 2026
- 8-K · SEC filingJun 18, 2026
Get alerts when SLS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days